Universität zu Köln

Engelke, A., Mueller, C. and Hallek, M. (2012). Chronic lymphocytic leukemia. Onkologe, 18 (12). S. 1115 - 1120. NEW YORK: SPRINGER. ISSN 0947-8965

Full text not available from this repository.

Abstract

Chronic lymphocytic leukemia is a low grade Non-Hodgkin lymphoma and the most frequent form of leukemia in western countries. The disease is characterized by a highly variable individual course. Clinical research has led to improvements in diagnostics, determination of risk profile and more effective therapy options. Chemoimmunotherapy is used as standard therapy for patients in advanced stages of the disease while the watch and wait strategy is the standard of care for patients in early stages of the disease or without clinical symptoms. Enrolment of patients in clinical trials is essential to allow further development of potential new therapies. It is anticipated that besides the clinical staging system new scores, models and methods, such as the minimal residual disease (MRD) assessment will gain importance in evaluation of the individual risk profile and treatment response.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Engelke, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mueller, C. UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-477387
DOI:	10.1007/s00761-012-2341-8
Journal or Publication Title:	Onkologe
Volume:	18
Number:	12
Page Range:	S. 1115 - 1120
Date:	2012
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	0947-8965
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language B-CELL LEUKEMIAS; MONOCLONAL-ANTIBODY; PROGRESSION-FREE; SURVIVAL; FEATURES; TRIAL; CD20 Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/47738